merged_ftc-pharmacy-benefit-managers-drug-prices.txt
<other>The article states the FTC "has so far stopped short of bringing a lawsuit or other enforcement action against a benefit manager." Therefore, there is no reason provided for a lawsuit since no lawsuit was brought.</other>
<question_number>1</question_number>
<answer>N/A</answer>
<other>The article mentions "By the end of 2018, each had become part of the same company as a giant insurer" regarding CVS Health's Caremark, but does not specify the year of acquisition for Caremark by CVS Health.</other>
<question_number>2</question_number>
<answer>N/A</answer>
<other>The article states the practice translated into "$1.6 billion in revenue over less than three years for the biggest three conglomerates" for two generic cancer drugs, but this is revenue for the PBMs, not an estimate of patient overpayment for generic drugs specifically.</other>
<question_number>3</question_number>
<answer>N/A</answer>